SMS Pharmaceuticals Limited (BOM:532815)
India
· Delayed Price · Currency is INR | Market Cap | 22.54B |
| Revenue (ttm) | 7.89B |
| Net Income (ttm) | 691.36M |
| Shares Out | n/a |
| EPS (ttm) | 8.16 |
| PE Ratio | 32.60 |
| Forward PE | n/a |
| Dividend | 0.40 (0.15%) |
| Ex-Dividend Date | Sep 23, 2024 |
| Volume | 3,687 |
| Average Volume | 11,898 |
| Open | 257.85 |
| Previous Close | 253.90 |
| Day's Range | 247.50 - 257.90 |
| 52-Week Range | 175.00 - 398.00 |
| Beta | n/a |
| RSI | 51.58 |
| Earnings Date | May 27, 2025 |
About SMS Pharmaceuticals
SMS Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients (APIs) and its intermediates in India and internationally. The company offers anti-retroviral, anti-inflammatory, anti-viral, anti-diabetic, anti-fungal, anti-epileptic, anti-migraine, anti-coagulant, anti-psychotic, anti-aginal, and anti-ulcer products. It is also involved in contract research activities on peptides. The company exports its products to approximately 75 countries. SMS Pharmaceuticals Limited was incorporated in 1987 and is headquartered in Hyde... [Read more]
Financial Performance
In 2024, SMS Pharmaceuticals's revenue was 7.89 billion, an increase of 11.24% compared to the previous year's 7.09 billion. Earnings were 691.36 million, an increase of 38.75%.
Financial StatementsNews
SMS Pharmaceuticals’ Visakhapatnam facility receives WHO prequalification
SMS Pharmaceuticals Limited announced that its Unit VII manufacturing facility in Visakhapatnam, Andhra Pradesh, has received prestigious prequalification approval from the World Health Organisation (...